Core Viewpoint - BiomX Inc. is facing non-compliance with NYSE American's continued listing standards due to insufficient stockholders' equity, necessitating a compliance plan submission by April 24, 2026 [1][2] Group 1: Compliance Issues - The company received a notice indicating it does not meet the stockholders' equity requirements of at least $2.0 million, $4.0 million, or $6.0 million based on its reported losses over recent fiscal years [1] - The company must submit a plan to regain compliance by September 25, 2027, or face potential delisting proceedings [2] Group 2: Current Status - The notice does not immediately affect the trading of the company's common stock, which will continue to trade under the symbol "PHGE" [3] - The company is reviewing options to address the deficiencies and plans to submit a compliance plan by the deadline [3] Group 3: Audit Qualification - The company's annual report for the fiscal year ended December 31, 2025, included a going concern qualification from its independent auditor [4] - This announcement is made to comply with specific sections of the Company Guide regarding disclosures related to audit opinions [4]

Core Viewpoint - Forte Minerals Corp. is advancing community engagement and permitting at the Alto Ruri Project, focusing on securing a long-term community agreement to explore a high-sulphidation epithermal gold system [1] Group 1: Alto Ruri Project - The Alto Ruri Project is located approximately 15 kilometers from Barrick's past producing Pierina Gold Mine and features a 2 km by 1.5 km advanced argillic alteration zone that has not been systematically tested with modern geophysics and drilling [1] - Historical drilling by Compañía de Minas Buenaventura in 1997 confirmed high-grade gold potential, with Hole 001-97 returning 131 meters of 2.55 g/t Au, including 54 meters of 5.39 g/t Au [2] Group 2: Pucarini High-Sulfidation Gold Project - Forte completed a five-hole, 1,530-meter exploration drill program at the Pucarini Project, confirming the presence of the targeted hydrothermal system, although only one hole returned anomalous gold, copper, and molybdenum values [3] - Management expressed pride in executing a safe and cost-effective program at Pucarini while maintaining a strategic focus on advancing the Alto Ruri project [4] Group 3: Financial Position and Strategic Focus - Forte is backed by two recent strategic investors and has a strengthened balance sheet, positioning the company to execute its 2026 exploration goals at Alto Ruri and evaluate additional opportunities across its copper-gold portfolio [5] - The company is committed to responsible resource development that generates long-term value for shareholders, communities, and partners [7]

Core Viewpoint - Calidi Biotherapeutics is making significant progress in advancing its lead asset CLD-401 towards clinical trials, with a focus on innovative approaches in cancer treatment and strategic partnerships to enhance its development pipeline [2][4]. Fourth Quarter 2025 Financial Results - The company reported a net loss of $4.1 million, or $0.57 per share, for Q4 2025, which is an improvement from a net loss of $4.1 million, or $3.23 per share, in Q4 2024 [3]. - Research and development expenses increased to $2.4 million in Q4 2025 from $1.8 million in Q4 2024 [6]. - General and administrative expenses slightly decreased to $2.1 million in Q4 2025 from $2.2 million in Q4 2024 [6]. Full Year 2025 Financial Results - For the full year 2025, the company reported a net loss of $25.6 million, or $5.95 per share, compared to a net loss of $23.8 million, or $35.70 per share, in 2024 [7]. - Research and development expenses for the year were $9.7 million, up from $8.9 million in 2024 [7]. - General and administrative expenses decreased to $10.5 million in 2025 from $12.9 million in 2024 [8]. Cash Position - As of December 31, 2025, the company had approximately $5.6 million in cash, down from $9.6 million as of December 31, 2024 [8]. Strategic Partnerships and Developments - Calidi has partnered with Avance Clinical to expedite the initiation of the CLD-401 clinical trial in Australia, leveraging their expertise in regulatory approval [4][5]. - The company is also collaborating with Matica Bio for GMP manufacturing of CLD-401, which is designed to target tumor cells specifically [5]. - Calidi presented new data on in situ T-cell engagers at the 2026 AACR-IO conference, showcasing advancements in their therapeutic approach [4][5]. Pipeline and Product Focus - CLD-401, the lead candidate from the RedTail platform, is currently in IND-enabling studies and targets various cancers with high unmet medical needs [10]. - The RedTail platform aims to deliver genetic medicines effectively to metastatic sites while minimizing peripheral exposure [9].

Core Viewpoint - Aqua Metals, Inc. is set to report its financial results for Q4 and the full year of 2025 on March 31, 2026, and will host a conference call to discuss these results and provide a business update [1]. Group 1: Company Overview - Aqua Metals is a pioneer in battery metals recycling and refining, utilizing its proprietary AquaRefining™ technology [2]. - The company focuses on delivering high-purity, low-carbon battery materials to meet the increasing demand for sustainable energy storage [2]. - Aqua Metals' innovation-driven approach aims to reduce emissions, eliminate waste streams, and support a circular supply chain for critical minerals essential for electric vehicles and grid storage [2].

Core Viewpoint - iAnthus Capital Holdings, Inc. reported its financial results for the fourth quarter and fiscal year 2025, highlighting a decline in revenue and net loss compared to the previous year [1]. Fiscal Year 2025 Financial Highlights - Revenue for FY2025 was $144.0 million, a decrease of 14.1% from FY2024 [5]. - Gross profit was $65.7 million, down 12.5% from the prior year, with a gross margin of 45.6%, an increase of 80 basis points from FY2024 [5]. - The net loss for FY2025 was $40.2 million, compared to a net loss of $7.6 million in FY2024 [5]. Fourth Quarter 2025 Financial Highlights - Revenue for Q4 2025 was $35.3 million, a slight sequential decrease of $0.1 million from Q3 2025 and a decrease of $7.4 million from Q4 2024 [5]. - Gross profit for Q4 2025 was $15.1 million, a sequential decrease of $0.5 million from Q3 2025 and a decrease of $4.1 million from Q4 2024 [5]. - The net loss for Q4 2025 was $14.1 million, compared to a net loss of $12.5 million in Q3 2025 and a net income of $27.8 million in Q4 2024 [5]. Adjusted EBITDA - Adjusted EBITDA for FY2025 was $13.0 million, down $10.9 million from FY2024 [5]. - Adjusted EBITDA for Q4 2025 was $5.4 million, an increase from $2.5 million in Q3 2025 but a decrease from $6.4 million in Q4 2024 [5].

Core Viewpoint - Cue Biopharma has appointed Lucinda Warren as interim president and CEO following the resignation of Usman Azam, with a focus on advancing the company's lead asset, CUE-401, into clinical trials by the second half of 2026 [1][2]. Company Leadership Transition - Lucinda Warren, previously the chief financial and business officer, has taken over as interim president and CEO after Usman Azam stepped down [1][2]. - The board of directors expressed gratitude for Usman Azam's contributions and showed full support for Lucinda Warren during this transition [2]. Strategic Initiatives - Under Lucinda Warren's leadership, Cue Biopharma aims to continue progressing CUE-401 towards clinical trials and pursue strategic collaborations to enhance shareholder value [2]. - Warren has a strong track record of executing significant deals, including the return of worldwide rights for CUE-401 and collaborations with Boehringer Ingelheim and ImmunoScape [2]. Company Overview - Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing a novel class of therapeutic biologics to engage and modulate disease-specific T cells for autoimmune and inflammatory diseases [3]. - The company's proprietary platform, Immuno-STAT®, aims to harness the immune system's potential while minimizing adverse effects associated with broad systemic immune modulation [3]. Product Development - CUE-401 is the lead asset designed to regulate proinflammatory mechanisms and induce tolerance through a bifunctional molecule combining TGF-beta and interleukin 2 (IL-2) [3].

Core Viewpoint - SPAR Group, Inc. is set to release its 2025 fourth quarter and fiscal year results on March 31, 2026, before market opening, followed by a conference call with management [1] Company Overview - SPAR Group is an innovative services company that provides comprehensive merchandising, marketing, and distribution solutions to retailers and brands across the United States and Canada [2] - The company focuses on improving brand experiences and transforming retail spaces through resources and analytics [2] - SPAR Group differentiates itself from competitors by offering a unique combination of scale and flexibility, emphasizing client results [2] Investor Relations - Investors can submit questions for management to address during the conference call by emailing Sandy Martin [3] - The conference call will be hosted by CEO William Linnane and CFO Steve Hennen at 9am ET on March 31, 2026 [1] - A replay of the call will be available until April 7, 2026, with access details provided [3]

Core Viewpoint - PMGC Holdings Inc.'s subsidiary, NorthStrive Biosciences, has announced a third amendment to its License Agreement with MOA Life Plus Co., Ltd. to update the development timeline and milestones for its clinical programs EL-32 and EL-22 [1][2]. Company Overview - PMGC Holdings Inc. is a diversified holding company that focuses on managing and growing its portfolio through strategic acquisitions and investments across various industries [5]. - NorthStrive Biosciences Inc. is a biopharmaceutical company under PMGC, concentrating on the development of innovative aesthetic medicines, with its lead asset EL-22 targeting obesity treatment while preserving muscle during weight loss [4]. Partnership Details - The amendment to the License Agreement aligns the development schedule of EL-32 and EL-22 with the research and regulatory expectations of both parties, reinforcing NorthStrive's commitment to disciplined development planning [2]. - MOA Life Plus Co. Ltd. is a Korean biotechnology firm dedicated to the research and commercialization of therapeutic and wellness technologies, partnering globally to enhance scientific innovation in health applications [3].

Core Insights - Entera Bio Ltd. is advancing its pipeline of oral peptide therapies, with significant developments in programs targeting osteoporosis, hypoparathyroidism, and metabolic syndromes [2][3][13] Group 1: Product Development Updates - EB613, the first oral anabolic peptide tablet for osteoporosis, has a streamlined Phase 3 protocol submitted to the FDA, with results expected in late 2028, one year earlier than previously anticipated [3][4] - The FDA has aligned with Entera on using bone mineral density (BMD) as the primary endpoint for EB613, marking a significant milestone in the drug's development [3] - EB612, an oral long-acting PTH replacement tablet for hypoparathyroidism, is set to file an IND application in late 2026, in collaboration with OPKO [5][10] - EB618, an oral dual GLP-1/glucagon peptide tablet for metabolic syndromes, has completed PK/PD validation, with Phase 1 initiation expected following injectable formulation data [6] Group 2: Financial Performance - As of December 31, 2025, Entera reported cash and cash equivalents of $14.9 million, with $7.8 million in restricted cash for OPKO collaboration [8] - The net loss for the year ended December 31, 2025, was $11.4 million, consistent with the previous year, reflecting ongoing investment in R&D and operational activities [9][12] - Research and development expenses increased to $6.0 million in 2025, primarily due to regulatory preparations for EB613 and internal program costs [11] Group 3: Clinical Data and Efficacy - Phase 2 data for EB613 demonstrated significant increases in bone indices after six months of treatment, comparable to injectable therapies [10] - New analyses showed EB613's effectiveness in increasing BMD in younger postmenopausal women, highlighting its potential as a preventive treatment for osteoporotic fractures [10]

Core Insights - E-Power Inc. has announced a strategic partnership with Raytel Electronics to co-launch high-speed optical modules for the North American AI infrastructure market [1][2][5] Group 1: Partnership Overview - The collaboration aims to integrate Raytel's optical communication technology with E-Power's power solutions, addressing data throughput and energy efficiency challenges in AI Data Centers [2][5] - The partnership will introduce 800G and 1.6T optical modules, designed for ultra-low power consumption and high-density AI clusters, reducing operational overhead in large-scale GPU environments [7] Group 2: Market Positioning - The global market for high-speed optical transceivers is projected to exceed $35 billion by 2030, positioning E-Power and Raytel at the forefront of this growth [7] - The joint initiative will focus on deploying these high-speed modules in the U.S., leveraging E-Power's established infrastructure to serve major hyperscalers and AI service providers [7] Group 3: Technical Integration - A joint technical task force will be formed to ensure Raytel's optical hardware is harmonized with E-Power's smart energy management systems, enhancing overall data center Power Usage Effectiveness (PUE) [7]